Literature DB >> 9462276

Beta 2 microglobulin haemodialysis related amyloidosis: distinctive gross features of gastrointestinal involvement.

M Shimizu1, T Manabe, T Matsumoto, Y Monobe, M Hirokawa, T Moriya, M Iida.   

Abstract

Two cases of beta 2 microglobulin amyloidosis following long term haemodialysis found during necropsy are reported. The patients were 59 and 65 year old Japanese men, respectively. In both cases, systemic distribution of beta 2 microglobulin amyloid deposits was observed. The gastrointestinal tract including the stomach, small intestine, and colon showed the distinctive gross feature of rippled appearance, which was characterised by serosal wrinkles along the muscle layer arrangement. These areas were confirmed to contain deposits of beta 2 microglobulin in the muscularis propria. Although the outline of the muscle layers was preserved, most muscle fibres, encircled by the amyloid deposits, were atrophic or had disappeared microscopically. In neither case could a definite diagnosis of amyloidosis be made while the patient was alive. Interestingly, the oesophagus presented less involvement compared to the remainder of the gastrointestinal tract. In comparison with the AA or AL type of amyloidosis, beta 2 microglobulin haemodialysis related amyloidosis showed a rippled appearance of the serosal rather than mucosal changes, which may explain the difficulty in diagnosing amyloid deposits using biopsies of the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462276      PMCID: PMC500275          DOI: 10.1136/jcp.50.10.873

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Systemic amyloidosis of beta 2 microglobulin type.

Authors:  K Mazanec; J McClure; C J Bartley; M J Newbould; P Ackrill
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

2.  Gastrointestinal complications of dialysis related amyloidosis.

Authors:  E R Maher; S H Dutoit; R A Baillod; P Sweny; J F Moorhead
Journal:  BMJ       Date:  1988-07-23

3.  Systemic amyloidosis of beta 2-microglobulin type: a complication of long-term haemodialysis.

Authors:  J M Theaker; A E Raine; A J Rainey; A Heryet; A Clark; D O Oliver
Journal:  J Clin Pathol       Date:  1987-10       Impact factor: 3.411

4.  Gastrointestinal involvement of dialysis-related amyloidosis.

Authors:  S Takahashi; T Morita; Y Koda; H Murayama; Y Hirasawa
Journal:  Clin Nephrol       Date:  1988-09       Impact factor: 0.975

5.  Protein-losing enteropathy due to secondary amyloidosis of the gastrointestinal tract.

Authors:  M Kawaguchi; F Koizumi; M Shimao; S Hirose
Journal:  Acta Pathol Jpn       Date:  1993-06

6.  Gastrointestinal amyloidosis: radiologic features by chemical types.

Authors:  S Tada; M Iida; T Yao; K Kawakubo; T Yao; T Fuchigami; M Okada; M Fujishima
Journal:  Radiology       Date:  1994-01       Impact factor: 11.105

Review 7.  Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature.

Authors:  R Gal; A Korzets; A Schwartz; L Rath-Wolfson; U Gafter
Journal:  Arch Pathol Lab Med       Date:  1994-07       Impact factor: 5.534

8.  Visceral involvement of dialysis amyloidosis.

Authors:  J M Campistol; A Cases; A Torras; M Soler; J Muñoz-Gómez; J Montoliu; J López-Pedret; L Revert
Journal:  Am J Nephrol       Date:  1987       Impact factor: 3.754

9.  Colonic dilatation due to dialysis-related amyloidosis.

Authors:  N Ikegaya; S Kobayashi; A Hishida; E Kaneko; M Furuhashi; Y Maruyama
Journal:  Am J Kidney Dis       Date:  1995-05       Impact factor: 8.860

  9 in total
  1 in total

1.  Endoscopic Findings of Small-Bowel Lesions in Familial Amyloid Polyneuropathy: A Case Report.

Authors:  Kensuke Asakura; Shunichi Yanai; Shotaro Nakamura; Keisuke Kawaski; Makoto Eizuka; Kazuyuki Ishida; Tamotsu Sugai; Mitsuharu Ueda; Taro Yamashita; Yukio Ando; Takayuki Matsumoto
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.